New Class of Antipsychotic in Development Enters Phase 3 Trials

http://online.wsj.com/article/SB10001424052748703778104576287070215410378.html
"After seeing signs of promise in earlier tests, Indianapolis-based Lilly recently started large-scale, late-stage clinical trials of the drug, code-named LY2140023, some of which are expected to be completed by early 2013....
LY2140023 is designed to stimulate substances in the brain known as metabotropic glutamate receptors, or mGlu for short. This approach differs from atypicals, which generally block the effects of the chemical dopamine in the brain."